Pancreatic Cancer Research

ResearcherUniversity of British ColumbiaActive in the last 2 years

James Thomas Topham

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0001-6601-8807; OpenAlex author ID A5081831776. Sources: OpenAlex.

Their work

Papers
21 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
65
Papers, trials and grants by year

2019: 2 papers · 2020: 3 papers · 2021: 5 papers · 2022: 2 papers · 2023: 1 paper · 2024: 3 papers · 2025: 3 papers · 2026: 2 papers

Papers 21

  1. DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarc… First author DOI 10.1038/s41467-026-70120-z↗
  2. Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-26-0793↗
  3. Multi-omics whole-genome characterization of the copy number landscape of metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2025.113176↗
  4. The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. Co-author DOI 10.1038/s41698-025-00888-8↗
  5. KRAS-induced STN1 (OBFC1) promotes proper CTC1-STN1-TEN1 complex-independent DNA double-strand break repair and cell cycle checkpoint maintenance in pancreatic… Co-author DOI 10.1093/nar/gkaf983↗
  6. A Deep Learning Approach for the Identification of the Molecular Subtypes of Pancreatic Ductal Adenocarcinoma Based on Whole Slide Pathology Images. Co-author DOI 10.1016/j.ajpath.2024.08.006↗
  7. Nutrient scavenging-fueled growth in pancreatic cancer depends on caveolae-mediated endocytosis under nutrient-deprived conditions. Co-author DOI 10.1126/sciadv.adj3551↗
  8. Pancreatic cancer tumor organoids exhibit subtype-specific differences in metabolic profiles. Co-author DOI 10.1186/s40170-024-00357-z↗
  9. Circulating tumor DNA: toward evolving the clinical paradigm of pancreatic ductal adenocarcinoma. Co-author DOI 10.1177/17588359231157651↗
  10. The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal a… Co-author DOI 10.1038/s41467-022-32591-8↗
  11. Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma. Co-author DOI 10.1038/s41467-022-33718-7↗
  12. Tumor infiltrating neutrophils and gland formation predict overall survival and molecular subgroups in pancreatic ductal adenocarcinoma. First author DOI 10.1002/cam4.3695↗
  13. Stroma vs epithelium-enhanced prognostics through histologic stratification in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33304↗
  14. Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma. Co-author DOI 10.1136/gutjnl-2020-320730↗
  15. Delving into Early-onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In? First author DOI 10.1158/1078-0432.ccr-20-1042↗
  16. Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics. Co-author DOI 10.1158/1078-0432.ccr-20-2831↗
  17. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Co-author DOI 10.1038/s41588-019-0566-9↗
  18. Author Correction: Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Co-author DOI 10.1038/s41588-020-0588-3↗
  19. Altered Gene Expression along the Glycolysis-Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer. First author DOI 10.1158/1078-0432.ccr-19-1543↗
  20. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia. Co-author DOI 10.1053/j.gastro.2019.05.004↗
  21. NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-19-0191↗

Closest collaborators

The 25 strongest of 65 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David F. Schaeffer · 21 shared papers, 2019–2026 · strength 2.91
  2. Daniel John Renouf · 21 shared papers, 2019–2026 · strength 2.91
  3. Joanna M. Karasinska · 19 shared papers, 2019–2026 · strength 2.49
  4. Jennifer Jane Knox · 13 shared papers, 2019–2026 · strength 1.56
  5. Steve Gallinger · 11 shared papers, 2019–2026 · strength 1.23
  6. Faiyaz Notta · 10 shared papers, 2020–2026 · strength 1.16
  7. Janessa J. Laskin · 10 shared papers, 2019–2025 · strength 1.04
  8. Steve E. Kalloger · 9 shared papers, 2019–2025 · strength 1.03
  9. Grainne Mary O'Kane · 9 shared papers, 2020–2025 · strength 0.96
  10. Rachel Anne Goodwin · 5 shared papers, 2021–2025 · strength 0.64
  11. Oliver F. Bathe · 5 shared papers, 2021–2025 · strength 0.64
  12. George Zogopoulos · 5 shared papers, 2020–2026 · strength 0.61
  13. Sharlene Gill · 4 shared papers, 2019–2026 · strength 0.60
  14. Hui‐Li Wong · 6 shared papers, 2019–2022 · strength 0.57
  15. Ravi Ramjeesingh · 3 shared papers, 2022–2026 · strength 0.54
  16. Mustapha Ali Tehfe · 3 shared papers, 2022–2026 · strength 0.54
  17. Petr Kavan · 3 shared papers, 2022–2026 · strength 0.54
  18. Christina Kim · 3 shared papers, 2022–2026 · strength 0.54
  19. Félix Couture · 3 shared papers, 2022–2026 · strength 0.54
  20. Derek J. Jonker · 3 shared papers, 2022–2026 · strength 0.54
  21. Chris J. O’Callaghan · 3 shared papers, 2022–2026 · strength 0.54
  22. Erica S. Tsang · 4 shared papers, 2021–2025 · strength 0.46
  23. Hassan A. Ali · 3 shared papers, 2022–2025 · strength 0.46
  24. Michael K.C. Lee · 5 shared papers, 2019–2021 · strength 0.45
  25. Sandra Elisabeth Fischer · 4 shared papers, 2020–2025 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.